Qulipta costs about $1,185 per month at retail price, regardless of whether you take the 10 mg, 30 mg, or 60 mg dose. That works out to roughly $14,200 per year before insurance. The price reflects a combination of factors: it’s a newer, patent-protected drug with no generic alternative, it belongs to an entirely new class of migraine treatments, and the company that makes it (AbbVie) faces little competitive pressure to lower the price.
What Makes Qulipta Different From Cheaper Options
Older migraine prevention drugs like propranolol (a blood pressure medication), topiramate (a seizure medication), and amitriptyline (an antidepressant) cost a few dollars a month as generics. But none of them were designed for migraine. They were borrowed from other conditions because doctors noticed they happened to reduce headache frequency. They take weeks to work, often require slow dose increases to manage side effects, and many people quit them because of weight changes, drowsiness, or cognitive fog.
Qulipta was built from the ground up to block a specific protein involved in migraine attacks called CGRP. This targeted approach means it works faster and carries a cleaner side-effect profile, particularly for people with heart disease or other conditions that make older preventives risky. That precision comes at a cost. Developing a drug against a new biological target requires years of research, clinical trials across thousands of patients, and a lengthy FDA approval process. AbbVie prices the drug to recoup that investment while it still holds exclusive rights to sell it.
Patent Protection Blocks Generic Competition
The single biggest reason Qulipta stays expensive is that no other company can legally make a generic version. FDA records show that the key patents on Qulipta don’t expire until July 2041 for the 30 mg and 60 mg tablets, and February 2043 for the 10 mg tablet. Until those dates pass (or a generic manufacturer successfully challenges the patents in court), AbbVie has no pressure from cheaper alternatives to lower the price.
For context, generic drugs typically cost 80% to 85% less than their brand-name counterparts. A generic version of Qulipta could eventually bring the monthly cost down to a fraction of what it is today, but that’s still roughly 16 to 18 years away.
Limited Competition Within the Drug Class
Qulipta’s only direct oral competitor for migraine prevention is Nurtec ODT (rimegepant), which carries a similar price tag. When two brand-name drugs compete in the same space, neither company has much incentive to cut prices dramatically. An indirect comparison analysis published in NeurologyLive found that Qulipta actually delivers more value per dollar: the cost per patient who achieves at least a 50% reduction in migraine days was about $15,800 for Qulipta versus $73,000 for Nurtec ODT. That’s a meaningful difference in efficiency, but it doesn’t change the sticker shock of either drug’s list price.
Injectable CGRP treatments like Aimovig, Ajovy, and Emgality compete in the same prevention space but cost in a similar range. The entire CGRP drug class sits at a premium tier, so there’s no bargain alternative within it.
Insurance Coverage Often Requires Extra Steps
Most insurance plans don’t cover Qulipta without friction. Insurers typically require step therapy, meaning you have to try and fail cheaper medications first. Aetna’s policy, which is representative of many commercial plans, requires at least 56 days on one of the older generic preventives (a beta-blocker, antidepressant, or anti-seizure drug) before it will pay for Qulipta. If you haven’t filled one of those prescriptions recently, you’ll need prior authorization from your doctor.
To get approved through prior authorization, you generally need to show one of three things: you tried an older preventive for at least eight weeks and it didn’t work well enough, you had side effects or a medical reason that prevents you from taking those drugs, or you’re already on Qulipta and it’s reducing your migraine days. Your doctor handles the paperwork, but the process can take days or weeks, and denials aren’t uncommon on the first attempt.
How to Lower Your Out-of-Pocket Cost
If you have commercial insurance (not Medicare or Medicaid), AbbVie offers a savings card that can reduce your copay to as little as $0 per month. The card covers up to $7,000 per calendar year, which is enough to eliminate most or all of your cost-sharing for the year. You can enroll through AbbVie’s website, and most specialty pharmacies apply the card automatically at checkout.
If you’re uninsured or underinsured, AbbVie’s patient assistance program (myAbbVie Assist) provides the drug at no cost to qualifying households. The income limits are relatively generous:
- 1 person: $63,840 or less per year
- 2 people: $86,560 or less
- 3 people: $109,280 or less
- 4 people: $132,000 or less
Each additional household member adds $22,720 to the threshold. A family of four earning six figures could still qualify, which makes this program worth checking even if you assume you earn too much.
Why the Price Is Unlikely to Drop Soon
Drug pricing in the U.S. is shaped by patent exclusivity, insurance negotiations, and the absence of government price caps on most medications. Qulipta checks every box for sustained high pricing: it treats a chronic condition requiring ongoing refills, it has patent protection stretching into the 2040s, and its competitors cost just as much. AbbVie negotiates rebates with insurers behind the scenes, so the net price health plans actually pay is lower than the $1,185 list price. But those discounts rarely reach patients directly, especially those with high-deductible plans or no insurance.
If you’re weighing whether Qulipta is worth the cost, the practical question is what you’ll actually pay after insurance and savings programs, not the list price. For many commercially insured patients using the savings card, the real monthly cost is $0 to $30. For those without coverage or assistance, the full retail price makes it one of the more expensive daily medications on the market.